Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis

被引:0
作者
L. Karlsson
J. Lundkvist
E. Psachoulia
M. Intorcia
O. Ström
机构
[1] Quantify Research,Department of Learning, Informatics, Management and Ethics (LIME), Medical Management Centrum (MMC)
[2] Karolinska Institutet,Department of Pharmacy
[3] Uppsala University,undefined
[4] Amgen (Europe) GmbH,undefined
来源
Osteoporosis International | 2015年 / 26卷
关键词
Bisphosphonates; Denosumab; Meta-analysis; Persistence; Retrospective; Review;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:2401 / 2411
页数:10
相关论文
共 332 条
[1]  
Kanis JA(2013)European guidance for the diagnosis and management of osteoporosis in postmenopausal women Osteoporos Int 24 23-57
[2]  
McCloskey EV(1998)Treatment of postmenopausal osteoporosis N Engl J Med 338 736-746
[3]  
Johansson H(2015)Treatment of primary osteoporosis in men Clin Interv Aging 10 105-115
[4]  
Cooper C(2008)Medication compliance and persistence: terminology and definitions Value Health 11 44-47
[5]  
Rizzoli R(2006)Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases Mayo Clin Proc 81 1013-1022
[6]  
Reginster JY(2012)Adherence to treatment of primary osteoporosis and its association to fractures—the Swedish Adherence Register Analysis (SARA) Osteoporos Int 23 433-443
[7]  
Eastell R(2006)Compliance with osteoporosis therapy is the weakest link Lancet 368 973-974
[8]  
Giusti A(2011)Osteoporosis: burden, health care provision and opportunities in the EU: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA) Arch Osteoporos 6 59-155
[9]  
Bianchi G(2011)Cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis Osteoporos Int 22 967-982
[10]  
Cramer JA(2012)The importance of integrating medication adherence into pharmacoeconomic analyses: the example of osteoporosis Expert Rev Pharmacoecon Outcomes Res 12 159-166